The use of hepatitis B immunoglobulin in the Netherlands.
Hepatitis B immunoglobulin (HBIg) was administered to 241 patients contaminated with HBAg positive material; 116 persons were followed up for 7 months after the HBIg injection. Only 4 (3.4%) cases of hepatitis B with jaundice and demonstrable HBAg occurred and 15 (12.9%) cases of subclinical hepatitis B were observed. HBIg is well tolerated. Passively transferred HBAb were demonstrable for 2-3 months and no chronic carriers of HBAg were seen after administration of HBIg.
D000410:Alanine Transaminase / Q000097:blood; D006509:Hepatitis B / Q000201:enzymology / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000032:analysis; D006511:Hepatitis B Antigens / Q000032:analysis; D006801:Humans; D005719:gamma-Globulins / Q000627:therapeutic use*
D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens; D005719:gamma-Globulins; D000410:Alanine Transaminase